Wealth of nonexecutive chairman of $2 billion (revenue) generics maker Cipla took a hit as a cut in drug prices by the government impacted domestic revenue, causing shares to fall. The company appointed a new CEO and named Hamied's niece Samina Vaziralli as executive vice chairman in September. Cipla is expanding overseas, notably in South Africa, where a new $90 million plant to make biosimilar drugs will be built in Durban. Cipla is also one of a group of companies that successfully bid for drugs divested by Israel's Teva Pharmaceutical.